Listen "270: Your guide to Wegovy’s blockbuster heart study"
Episode Synopsis
In the wake of a massively important clinical trial of Novo Nordisk’s obesity drug Wegovy, our colleague Elaine Chen joins us to explain what we know and don’t know about data that could change the practice of medicine. Then, Mizuho Securities biotech strategist Jared Holz calls in to discuss whether explosive popularity of obesity treatments could help create the first trillion-dollar drug company.
More episodes of the podcast The Readout Loud
382: Biotech's year in review
18/12/2025
ZARZA We are Zarza, the prestigious firm behind major projects in information technology.